LPTX Company Report

Cypherpunk Technologies (formerly Leap Therapeutics) reported a net loss of $3.3 million for the third quarter of 2025, a significant improvement from a $18.2 million net loss in the third quarter of 2024.
The company completed a $58.88 million private placement in October 2025, led by Winklevoss Capital, and has since acquired 203,775.27 ZEC for approximately $50 million as of November 11, 2025, as part of its new digital asset treasury strategy.
Effective November 13, 2025, the company will trade on the Nasdaq Capital Market under the new ticker symbol "CYPH", reflecting its strategic shift towards digital assets, while its cancer research will continue under a wholly-owned subsidiary.
In its biopharmaceutical operations, final data from the Phase 2 DeFianCe study of sirexatamab demonstrated statistically significant benefits in overall response rate and progression-free survival for DKK1-high colorectal cancer patients.
The company appointed Khing Oei as Chairman of the Board of Directors and Will McEvoy as Chief Investment Officer and Board member on November 11, 2025, to support its digital asset strategy.

Nov 12, 2025, 1:00 PM

Leap Therapeutics Rebrands as Cypherpunk Technologies, Adopts Zcash Treasury Strategy, and Appoints New Leadership

LPTX

New Projects/Investments

Board Change

Management Change

Leap Therapeutics, Inc. has rebranded as Cypherpunk Technologies Inc. and will begin trading under the new ticker symbol CYPH on Thursday, November 13.
The company has adopted a digital asset treasury strategy, using $50 million from a private placement to purchase 203,775.27 ZEC (Zcash's native coin) at an average price of $245.37 per ZEC.
This strategic shift was supported by a recently completed $58.88 million private placement led by Winklevoss Capital.
Khing Oei has been appointed Chairman of the Board, and Will McEvoy has been appointed Chief Investment Officer and a Member of the Board, with both appointments effective November 11, 2025.

Nov 12, 2025, 12:00 PM

Leap Therapeutics Presents Positive Final Data from DeFianCe Study for Sirexatamab

LPTX

Product Launch

New Projects/Investments

Leap Therapeutics announced positive final results from Part B of the DeFianCe study for sirexatamab (DKN-01) in patients with microsatellite stable colorectal cancer (CRC) at ESMO Congress 2025.
Sirexatamab demonstrated statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in the DKK1-high patient population.
For DKK1-high (upper median) patients, the Sirexatamab Arm achieved a median PFS of 9.03 months compared to 7.06 months in the Control Arm, and median OS was not reached compared to 14.39 months in the Control Arm.
Leap plans to engage with regulatory authorities to determine the registrational path for sirexatamab in CRC and to optimize the DKK1 biomarker diagnostic test.

Oct 20, 2025, 11:00 AM

Leap Therapeutics Closes $58.88 Million Private Placement and Initiates Digital Asset Treasury Strategy

LPTX

New Projects/Investments

Board Change

Leap Therapeutics closed a private placement on October 8, 2025, raising $58.88 million in cash.
The proceeds will be used to initiate a digital asset treasury strategy and continue the development of therapeutic programs, including FL-501 and sirexatamab.
As part of the transaction, Leap issued 15,212,311 shares of common stock, pre-funded warrants to purchase up to 80,768,504 shares, and warrants to purchase an additional 71,985,605 shares of common stock.
Winklevoss Capital, the lead investor, will provide strategic support for the digital asset strategy and has the right to nominate two individuals to Leap's Board of Directors, which has been increased to 12 members.

Oct 9, 2025, 11:09 AM

Leap Therapeutics Announces Private Placement and Digital Asset Treasury Strategy

LPTX

New Projects/Investments

Board Change

Leap Therapeutics announced a private placement securing $58,888,888 in cash commitments led by Winklevoss Capital to initiate a digital asset treasury strategy.
The private placement involves the issuance of 95,849,353 shares of common stock (or pre-funded warrants) and warrants to purchase an additional 71,887,008 shares at an exercise price of $0.5335 per share, with an aggregate exercise price per Unit of $0.61439.
A portion of the capital will also fund the continued development of Leap's therapeutic programs, FL-501 and sirexatamab.
Winklevoss Capital will have the right to nominate two individuals to Leap's Board of Directors, including the chairperson, which will increase the board size to 12 members.
The closing of the private placement is anticipated on or about October 8, 2025.

Oct 6, 2025, 1:08 PM

Leap Therapeutics Announces Private Placement and Digital Asset Treasury Strategy

LPTX

New Projects/Investments

Board Change

Leap Therapeutics secured $58,888,888 in cash commitments through a private investment in public equity (PIPE) offering led by Winklevoss Capital.
The capital will be used to initiate a digital asset treasury strategy and to continue the development of Leap's therapeutic programs, including FL-501 and sirexatamab.
As part of the agreement, Leap will increase its Board of Directors to 12 members, with Winklevoss Capital having the right to nominate two individuals, one of whom will be the chairperson.

Oct 6, 2025, 1:00 PM

Leap Therapeutics to Present Final Clinical Data for Sirexatamab at ESMO Congress 2025

LPTX

New Projects/Investments

Guidance Update

Leap Therapeutics (Nasdaq: LPTX) will present final clinical results from Part B of the DeFianCe study, a Phase 2 trial of its drug candidate sirexatamab (DKN-01), at the European Society for Medical Oncology (ESMO) Congress 2025.
The data pertains to sirexatamab in combination with bevacizumab and chemotherapy for patients with advanced microsatellite stable (MSS) colorectal cancer.
The presentation is scheduled for a Mini Oral Session on Sunday, October 19, 2025, at 4:05 p.m. CEST.
The company also stated its plan to reduce clinical and operational activities, conserve cash, and explore strategic alternatives, including potentially selling or partnering sirexatamab or FL-501.